Yasmine Mahmoud Massoud

Yasmine Mahmoud Massoud

Auto-generated profile, based on publicly available information

Yasmine Mahmoud Massoud

Ain Shams Center for Organ Transplantation (ASCOT), Ain Shams University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
IMIman F Montasser
Iman F Montasser
HDHany Dabbous
Hany Dabbous
MSMohammad M Sakr
Mohammad M Sakr
HEHend Ebada
Hend Ebada
YMYasmine M Massoud
Yasmine M Massoud
DZDoaa Zakaria Zaky
Doaa Zakaria Zaky

1 October 2021 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
AEAshraf Mahmoud El-Sayed
Ashraf Mahmoud El-Sayed
YMYasmine Mahmoud Massoud
Yasmine Mahmoud Massoud
AAAyat Abdallah Abd-Elkalik
Ayat Abdallah Abd-Elkalik
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, accounting for about 1 million related deaths annually. An estimated 372, 000 new cases of hepatocellular carcinoma (HCC) are diagnosed each year, constituting 4.6% of all new human cancers. Objectives: The aim of our study was to study the complications of Hepatocellular Carcinoma patients post living Donor Liver Transplantation at Ain Shams Center for Organ Transplantation. Patients and methods: The study population underwent Living donor liver Transplanation due to hepatitis C virus related hepatocellular carcinoma during the period from January 2008 to 2019.A total number of 114 patients underwent LDLT due to HCV related hepatocellular carcinoma.Fourteen patients(12.2%) were excluded because of the intraoperative death or postoperative early death, 7 patients(6%) were excluded because of overlapping etiologies with hepatitis C (HBV,autoimmune hepatitis,BCS,…etc) and 11 patients (9.6%) were excluded due to their age.Eighty two patients fulfilling the inclusion criteria for enrollment were recruited in the study. Results: The most common complications were (45.1%) neuropsychiatric side effects induced by immunosuppressive treatment, malignancy, hypertension, renal impairment, stroke, small for size disease…etc. Biliary complications (34.1%) as well as sepsis (34.1%) were the second common complications then rejection (18.3%), recurrence (12.2%), death (11%) and vascular complications (10%). Conclusion: There was no statistical significance for those within or out side the Milan criteria or UCSF criteria and its impact on the occurrence of graft rejection, sepsis, vascular complications, death, HCC recurrence and biliary complications post-transplant.

1 August 2023 in Journal of the Egyptian Society of Parasitology
Verified
Journal Article
Open access
PDF file
SMSafeya Ramadan Maghraby
Safeya Ramadan Maghraby
AIAmany Ahmad Ibrahim
Amany Ahmad Ibrahim
IMIman Mohamed Fawzy Montasser
Iman Mohamed Fawzy Montasser
ZHZeinab Mohamed Hefny
Zeinab Mohamed Hefny
MAMarwa Ali Abdelwahed
Marwa Ali Abdelwahed
YMYasmine Mahmoud Massoud
Yasmine Mahmoud Massoud
Liver cancer has been known to be the sixth cause of cancer worldwide. In Egypt, it is thefourth cause of cancer and the second -related mortality. The P53 is considered the guardian ofthe genome to prevent accumulation of oncogenic mutations that lead to malignant tumor.The study compared the circulating tumor DNA (ctDNA) by targeting hotspot mutation genelocus TP53 rs28934571 (c.747G>T) in normal persons, chronic liver disease patients, and inhepatocellular carcinoma (HCC) ones to evaluate its diagnostic value and analyses the ctDNAby targeting the hotspot mutation gene locus TP53 rs28934571 (c.747G>T).The results showed that of 100 adults, G1: Eighty (80%) patients were diagnosed as HCC ontop of HCV, ten (10%) as HCV patients and ten (10%) healthy controls. All groups were matchedas to age and sex. The AST was increased in HCC patients as compared to healthy control(P =0.018), forty patients (50%) were within Milan criteria, 12 patients (15%) withinUSCF, 28 (35%) were beyond all of whom 39 (48.75%) patients were child A with meanscore of 12.45±5.94. Forty (50%) patients had one focal lesion, 16 patients had two focal lesions,eight patients had four focal lesions and six patients had multiple lesions. The averagesize of lesion in cm was (5.58±3.66). Among the HCC patients 38 (47.5%) patients developedascites, 35 (43.75%) patients developed PVT and 9 (11.25%) patients developed encephalopathy.There was no significant difference in genetic typing between HCC patients, HCV onesand healthy controls (p =0.622).

11 May 2026 in Egyptian Liver Journal
Verified
Journal Article
Open access
PDF file
NMNahed A Makhlouf
Nahed A Makhlouf
IMIman F Montasser
Iman F Montasser
RRRasha Refaie
Rasha Refaie
YMYasmine M Massoud
Yasmine M Massoud
AMAhmed Marwan
Ahmed Marwan
GEGamal Esmat
Gamal Esmat
Background: Adult living donor liver transplantation (LDLT) started in Egypt in 2001, with more than 5000 cases transplanted since then. In Egypt using only ABO compatible donor is the practice in all cases, and up till now, the only oncological indication for LDLT is hepatocellular carcinoma (HCC). The optimal management of the transplant recipient relies on understanding and proper utilization of immunosuppression regimens. The clinician should be aware of how to maintain the delicate balance between under-immunosuppression, leading to graft rejection, and over-immunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The aim of this consensus is to provide clinical guidance to transplant physicians, transplant surgeons, clinical pharmacologists and nurses about immunosuppression in LDLT recipients. Main body: These national recommendations on immunosuppression in adult LDLT were developed by an experience exchange between the 22 centers currently undergoing LDLT in Egypt. A group of experts in liver transplantation from all over Egypt participated in the review of literature for different aspects related to these recommendations and, then they shared in formulation of several statements. In the United Conference on Hepato-gastroenterology and Infectious Diseases (UCHID) (2022), voting on these statements was done. Conclusion: Comprehensive national guidance is provided regarding the general principles of liver transplant immunosuppression, types of immunosuppression (IS), established IS drugs, types of rejection and their management, treatment of special groups, immunosuppression minimization, immune tolerance and complete IS withdrawal and the role of liver biopsy in orchestrating immunosuppression.